Kite Pharma Loss Widens

(RTTNews) - Kite Pharma Inc (KITE) on Friday reported first-quarter net loss of $15 million or $0.36 per share compared with a loss of $3.7 million or $0.66 per share last year.

Excluding items, adjusted loss for the quarter was $0.20 per share.

Revenues for the quarter were $2.9 million.

Analysts polled by Thomson Reuters estimated earnings of $0.12 per share on revenues of $19.7 million for the quarter. Analysts' estimates typically exclude special items.

Kite Pharma is a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer.